EmbryoCellect™ Performance Data Published and DOPlify™ Launched

Jul 04, 2016 -

Reproductive Health Science Limited (ASX: RHS) (“RHS” or “the Company”) has announced the release of a report on the validation of EmbryoCellect™ using euploid and aneuploid single cell and 5-10 cell aliquots.  This study is the most comprehensive of its type published and demonstrates the high accuracy of this RHS product. 

View the ASX Announcement

View the EmbryoCellect™ Validation Report

< Back to all news